eXoZymes (EXOZ) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
INmune Bio (INMB) has outperformed eXoZymes (EXOZ) over the past year, losing 5.1% versus a loss of 59.0%. eXoZymes is the larger company by market cap ($51.5 million vs $51.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXOZ | INMB |
|---|---|---|
| Share price | $5.54 | $1.84 |
| Market cap | $51.55M | $51.07M |
| 1-day change | 0.00% | -1.07% |
| YTD return | -49.17% | +19.23% |
| 1-year return | -58.96% | -5.10% |
| 5-year return | — | -90.01% |
| EPS (TTM) | $-1.19 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.40 | $2.60 |
| 52-week low | $4.35 | $1.09 |
| Distance from 52-week high | -69.89% | -29.23% |
| Average volume | 6.80K | 416.29K |
| Shares outstanding | 9.30M | 27.75M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed EXOZ by 53.9 percentage points over the past year.
EXOZ vs INMB FAQ
Which is bigger, eXoZymes or INmune Bio?
eXoZymes (EXOZ) is larger, with a market capitalization of $51.55M compared with $51.07M for INmune Bio (INMB).
Which stock has performed better over the past year, EXOZ or INMB?
INMB returned -5.10% over the past 12 months, compared with -58.96% for EXOZ (price return, excluding dividends). Past performance does not predict future results.
Are eXoZymes and INmune Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.